| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082877 | Drug Discovery Today: Therapeutic Strategies | 2011 | 5 Pages |
Abstract
The high cost of R&D combined with the tiny percentage of drugs that actually achieve regulatory approval has created an environment in which pharmaceutical companies are utilizing previously conducted research and other techniques to expedite the approval process, improve the chance of approval and buy additional years of marketing exclusivity by repositioning drugs with new indications, formulations or methods of administration.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Ken Phelps,